Journal
NUCLEIC ACID THERAPEUTICS
Volume 27, Issue 5, Pages 251-259Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/nat.2017.0682
Keywords
exon skipping; oligonucleotides; regulatory approval
Funding
- COST Action [BM1207]
- SCOPE-DMD
- National Institute for Health Research [NF-SI-0515-10022] Funding Source: researchfish
Ask authors/readers for more resources
Duchenne muscular dystrophy (DMD) is a rare, severe, progressive muscle-wasting disease leading to disability and premature death. Patients lack the muscle membrane-stabilizing protein dystrophin. Antisense oligonucleotide (AON)-mediated exon skipping is a therapeutic approach that aims to induce production of partially functional dystrophins. Recently, an AON targeting exon 51 became the first of its class to be approved by the United States regulators [Food and Drug Administration (FDA)] for the treatment of DMD. A unique aspect of the exon-skipping approach for DMD is that, depending on the size and location of the mutation, different exons need to be skipped. This challenge raises a number of questions regarding the development and regulatory approval of those individual compounds. In this study, we present a perspective on those questions, following a European stakeholder meeting involving academics, regulators, and representatives from industry and patient organizations, and in the light of the most recent scientific and regulatory experience.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available